New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

135.30 2.56 +1.93%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Latest quarter Q3 FY2026 · quarter to September 2026

Revenue growth has held between 3% and 6% for five quarters.

Q3 FY2026 and the seven quarters before it
Quarter Revenue, $m Growth, % Op. margin, % EPS, $
Q3 FY26 18,085 4.7 31.9 2.04
Q2 FY26 16,607 5.1 (2.6) (0.54)
Q1 FY26 16,286 4.9 (19.7) (1.72)
Q4 FY25 16,400 5.0 24.8 1.19
Q3 FY25 17,276 3.7 37.9 2.32
Q2 FY25 15,806 (1.9) 35.1 1.76
Q1 FY25 15,529 (1.6) 38.2 2.01
Q4 FY24 15,624 6.8 27.8 1.48

Against the consensus: revenue beat by 4.94% ($18.1B v $17.2B); adjusted EPS beat by $0.37 ($2.49 v $2.12).

Growth is on the same quarter a year earlier, and EPS is diluted. Negative figures in brackets.

Outlook

FY2027 revenue: Merck expects modest revenue growth in FY2027.

Company guidance, Q3 2026 earnings call.

Reports Feb 2, 2027 · Q4 FY26 · consensus EPS $1.78

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 328,620
Revenue ttm 67,378
Net income ttm 2,449
Free cash flow ttm 14,746
Net debt Q 40,039
Valuation
P/E 136.8 (above 35: high)
Forward P/E FY26e 105.0 (above 35: high)
Price / sales 4.9
Forward P/S FY26e Powerpack
Price / FCF 22.2
Price / book 7.3 (above 6: high)
Financial health
Current ratio Q 1.4
Debt / equity Q 1.1
Interest coverage Q —
Growth
Revenue growth FY26e +3.4%
EPS growth FY26e −69.0% (below 0%: weak)
EPS growth FY27e +219.6% (at or above 15%: strong)
EPS growth, 5 yrs e +3.4%
Insiders
Net sold 12m 79
Sells 12m 20
Buys 12m 0
Owned by insiders 0.3%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales 5.11% 9.38% 3.12%
Cash Flow 2.77% 16.68% (4.81%)
Earnings 15.18% 20.90% 7.93%
Book Value 1.64% 15.70% 4.57%

Valuation

The price implies free cash flow after share-based pay growing 9.6% a year for ten years. It grew 4.5% a year over the last ten.

Implied
9.6%
10 years, reported
4.5%
Open the model
P/E against its own 10 years 94.15%
10-year low 10-year high
P/S against its own 10 years 80.85%
10-year low 10-year high
P/B against its own 10 years 78.70%
10-year low 10-year high
EV/Sales against its own 10 years 86.15%
10-year low 10-year high
EV/FCF against its own 10 years 47.28%
10-year low 10-year high

Dividends raised every year since 2017

Yield
2.56%
Annual rate
3.40
Payout ratio
350.5%
Growth, 2017–25
+7.76%/yr
  1. 1.80 ’17
  2. 1.90 ’18 +5
  3. 2.16 ’19 +14
  4. 2.37 ’20 +10
  5. 2.61 ’21 +10
  6. 2.80 ’22 +7
  7. 2.96 ’23 +6
  8. 3.12 ’24 +5
  9. 3.28 ’25 +5
  10. 3.40 ’26e +4
paid forecast change on the year, % Powerpack

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 39,807 40,122 42,294 39,121 41,518 48,704 59,283 60,115 64,168 65,011 67,378 +5.6% 67,242 69,461 73,744 +4.3%
Gross margin, % 64.75 67.82 68.06 69.29 67.20 72.02 70.63 73.17 76.32 74.80 71.75 +10.1 pt
EBT 4,659 6,521 8,701 7,171 5,863 13,879 16,444 1,889 19,936 21,067 4,762 +18.3%
EBT margin, % 11.70 16.25 20.57 18.33 14.12 28.50 27.74 3.14 31.07 32.41 7.07 +20.7 pt
Net income 3,941 2,418 6,193 5,606 4,523 12,358 14,526 377 17,133 18,263 2,449 +18.6%
Per share, $
Per share, $ Revenue 14.39 14.70 15.88 15.25 16.41 19.25 23.41 23.70 25.34 25.98 27.30 +6.8%
Earnings 1.42 0.93 2.32 3.81 2.78 5.16 5.73 0.14 6.74 7.28 0.97 +19.9%
Cash flow 3.75 2.36 4.10 3.46 3.01 5.19 7.54 5.13 8.48 6.58 7.58 +6.4%
Capex (0.58) (0.69) (0.98) (1.31) (1.75) (1.76) (1.73) (1.52) (1.33) (1.64) (1.60) +12.2%
Free cash flow 3.17 1.67 3.12 2.15 1.26 3.43 5.81 3.60 7.15 4.94 5.97 +5.1%
Book value 14.57 12.66 10.09 10.14 10.04 15.12 18.19 14.83 18.31 21.05 18.21 +4.2%
Shares, m 2,766 2,730 2,664 2,565 2,530 2,530 2,532 2,537 2,532 2,502 2,478 (1.1%)
Valuation, ×
Valuation, × P/E 41.49 58.34 31.78 23.04 28.50 14.85 19.40 808.86 14.78 14.46 136.85 105.5
P/S 4.03 3.69 4.64 5.75 4.81 3.98 4.75 4.78 3.93 4.05 4.86 4.4
P/B 3.98 4.29 7.31 8.66 7.86 5.07 6.11 7.63 5.43 5.00 7.29 6.1
EV/Sales 4.28 4.01 4.90 6.07 5.23 4.45 5.01 5.22 4.25 4.55 5.46 4.8
EV/FCF 19.46 35.28 24.97 43.05 68.08 24.96 20.19 34.33 15.07 23.91 24.93 30.9
Cash, $m
Cash, $m Operating cash flow 10,376 6,451 10,922 8,884 7,617 13,122 19,095 13,006 21,468 16,472 18,703 +5.3%
Capex (1,614) (1,888) (2,615) (3,369) (4,429) (4,448) (4,388) (3,863) (3,372) (4,112) (3,957) +11.0%
Free cash flow 8,762 4,563 8,307 5,515 3,188 8,674 14,707 9,143 18,096 12,360 14,746 +3.9%
Balance, $m
Balance, $m Working capital 13,410 6,152 3,669 5,263 437 6,394 11,483 6,474 10,362 15,189 10,140 +1.4%
Net debt 9,933 12,855 10,942 12,286 17,310 22,594 15,553 26,590 20,773 32,185 40,039 +14.0%
Shareholders’ equity 40,308 34,569 26,882 26,001 25,404 38,257 46,058 37,635 46,372 52,662 44,946 +3.0%
Returns, %
Returns, % ROA 3.98 2.61 7.30 11.79 8.03 13.23 13.52 0.34 15.30 14.37 1.87 +10.4 pt
ROIC 6.84 8.96 14.76 12.94 8.12 13.56 18.55 2.87 18.82 16.28 4.56 +9.4 pt
ROE 9.22 6.39 20.24 37.23 27.50 41.00 34.44 0.87 40.75 36.86 5.07 +27.6 pt
People
People Employees 68,000 69,000 69,000 71,000 74,000 68,000 69,000 72,000 75,000 75,000 — +1.1%
Revenue/emp, $m 0.59 0.58 0.61 0.55 0.56 0.72 0.86 0.83 0.86 0.87 — +4.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026

Business profile

Updated

Merck & Co. is a global health care company that sells prescription medicines, vaccines and animal health products. Founded in 1891, it is headquartered in Rahway and led by Chairman, President and Chief Executive Officer Robert M. Davis.

Its human health business includes medicines for cancer, pulmonary arterial hypertension, diabetes, infections and other conditions. Keytruda, its cancer therapy, is given intravenously; Keytruda Qlex combines the same active cancer medicine with an ingredient that enables an injection under the skin. Merck also sells vaccines, including Gardasil for diseases caused by certain types of human papillomavirus, or HPV.

Where the money comes from and where it goes Fiscal 2025

Fiscal 2025: revenue by segment, and margins
Pharmaceutical 58,142 89.43%
Animal Health 6,354 9.77%
Other, not broken out 515 0.79%
Gross margin 74.80%
Operating margin 34.01%
Pre-tax margin 32.41%

Revenue by segment since 2016

Merck & Co., Inc. vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
JNJ Johnson & Johnson $650.7B 40.5× 41.8× FY26e +5.86% (above 0%: growing) −95.75% (below 0%: shrinking) −21.44% (below 0%: shrinking) 68.12% 1.72% Compare
ABBV AbbVie Inc. $501.2B 48.8× 37.6× FY26e +10.32% (above 0%: growing) +2,270.00% (above 0%: growing) +9.97% (above 0%: growing) 75.38% 36.01% Compare
MRK Merck & Co., Inc. $328.6B 137× 105× FY26e +4.68% (above 0%: growing) −12.07% (below 0%: shrinking) −19.27% (below 0%: shrinking) 72.95% 31.90%
NVS Novartis AG $277.7B 28.8× 24.0× FY26e +4.67% (above 0%: growing) −68.81% (below 0%: shrinking) −17.81% (below 0%: shrinking) 75.99% 12.26% Compare
AZN AstraZeneca PLC $272.1B 24.6× 24.2× FY26e +6.70% (above 0%: growing) +23.46% (above 0%: growing) +1.99% (above 0%: growing) 81.82% 27.07% Compare
AMGN Amgen Inc. $237.4B 25.2× 24.0× FY26e +8.45% (above 0%: growing) +19.39% (above 0%: growing) −13.98% (below 0%: shrinking) 73.10% 35.79% Compare
GILD Gilead Sciences, Inc. $207.8B — (loss-making) — (loss-making) +6.83% (above 0%: growing) −20.16% (below 0%: shrinking) +21.13% (above 0%: growing) 81.07% 41.71% Compare
PFE Pfizer Inc. $158.2B 38.8× 18.7× FY26e −0.43% (below 0%: shrinking) −9.68% (below 0%: shrinking) +20.02% (above 0%: growing) 75.71% 22.14% Compare
NVO Novo Nordisk A/S $128.6B 9.8× — +3.87% (above 0%: growing) −17.14% (below 0%: shrinking) −14.75% (below 0%: shrinking) 76.97% 29.06% Compare
Median of peers $254.7B 28.8× 24.1× +6.28% −13.41% −5.99% 75.85% 28.07%

All 21 Drug Manufacturers General stocks →

From the latest earnings call

Updated

  • CFO Caroline Litchfield said favorable purchase timing lifted third-quarter sales, with the Keytruda and Winrevair benefits expected to unwind in the fourth quarter.
  • Litchfield described 2027 as an investment year, with new products and animal health growth partly offset by generic competition and losses of exclusivity.

Analyst rating changes each firm’s latest, last six months

Firm Date Action Rating Target Change
Leerink Partners Nov 4, 2026 Target raised Buy 161.00 → 162.00 +0.62%
Barclays Oct 26, 2026 Target raised — 170.00 —
Goldman Sachs Oct 22, 2026 Target cut — 160.00 → 155.00 −3.13%
Scotiabank Oct 3, 2026 Target raised — 155.00 → 180.00 +16.1%

Largest institutional holders 13F, quarter to Jun 30, 2026

Held by institutions 79.89%
Held by the ten largest 39.76%
Holder Shares Stake Change
Vanguard 255.74m 10.37% +1.23m
BlackRock 227.00m 9.20% +1.17m
State Street 120.41m 4.88% +1.09m
Wellington Management 86.25m 3.50% +1.93m
Geode Capital Management 60.74m 2.46% +1.19m
Charles Schwab 54.37m 2.20% +4.60m
Morgan Stanley 48.64m 1.97% +1.01m
Fidelity (FMR) 45.44m 1.84% +924.35k
JPMorgan Chase 43.89m 1.78% −9.09m
Fisher Investments 38.52m 1.56% +12.08m
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Merck & Co., Inc. (MRK) Latest News

What happened

  1. Deal Merck entered a research collaboration with Isomorphic Labs to design small-molecule candidates for an undisclosed oncology target.
  2. Legal A German higher regional court overturned a preliminary injunction that had barred Merck from offering or distributing Keytruda SC in Germany.
  3. Other Merck discontinued nemtabrutinib development and its Phase 3 BELLWAVE trials after reviews concluded the benefit-risk profile did not support continuing.
  4. Other Merck received positive EU CHMP opinions for Welireg with lenvatinib in advanced kidney cancer and an expanded Enflonsia indication for vulnerable children up to 24 months.
  5. Results Merck reported third-quarter sales of $18.1 billion, up 5%, and raised its 2026 guidance.
17 more headlines
All MRK news, as stories →

MRK metrics, ten years each

stockrow.com/MRK · Data as of Nov 18, 2026 · For information only; not investment advice. · © 2026 stockrow.com